Devices Market(Device Type: Spinal Cord Stimulator, Deep Brain Stimulator, Sacral Nerve Stimulator, Vagus Nerve Stimulator & Gastric Electric Stimulators; Therapeutic Areas: Pain Management, Epilepsy, Essential Tremor, Urinary and Fecal Incontinence, Depression Dystonia, Gastroparesis, Parkinson's Disease & Others): Growth, Future Prospects and Competitive Analysis, 2016-2024," the global neurostimulation
devices market was valued at US$ 4,904.
M2 EQUITYBITES-September 8, 2017-Nexeon MedSystems Acquires Belgian Neurostimulation
Food and Drug Administration (FDA) for TrueTear Intranasal Tear Neurostimulator, the first and only FDA-cleared device developed to temporarily increase tear production during neurostimulation
in adult patients.
M2 PHARMA-January 19, 2017-Abbott to offer Proclaim DRG neurostimulation
device designed for DRG therapy and targeted relief of certain types of chronic pain
The market segmented based on the product type, into 2 type's biomaterial and neurostimulation
devices market is estimated to witness the highest growth and account for the largest share of the global pain management devices market, by type, in 2016.
Scientists haven't yet figured out how to give us flight, but we know that increased cognition, strength and motor function are all possible using neurostimulation
The application segments included in this report are direct nerve repair/neurorrhaphy, nerve grafting, stem cell therapy, and neurostimulation
The Asian nerve repair and regeneration market comprises various types of products that can be segmented into nerve repair by biomaterials and nerve repair by neurostimulation
, of which Nerve repair by Neurostimulation
holds the highest market share of 57 %, followed by nerve repair by biomaterials with a market share of 43 % .
Clinical evidence supporting the use of neurostimulation
devices is increasing their adoption rate among neurosurgeons.
BANKING AND CREDIT NEWS-January 15, 2015-Sensory NeuroStimulation
establishes credit facility with Silicon Valley Bank
They randomized 127 patients with early motor complications to best-practices drug therapy and 124 to that plus subthalamic neurostimulation